Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Why pharma needs to ‘walk the talk’ on improving the greener patient journey

By Kate Harrison

- PMLiVE

WHO member states commit to producing a pandemic accord in 2023

The ‘zero draft’ will be a legally binding agreement, part of the WHO Constitution

- PMLiVE

New UK study finds most MS patients not offered fatigue treatments

Of 4,367 patients surveyed, 30.8% reported having been offered at least one treatment for fatigue

- PMLiVE

Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma

There are 176,000 new cases of the disease worldwide for which there is currently no cure

- PMLiVE

UK Government launches new taskforce to help NHS tackle COVID-19 backlogs

Experts will focus on how the NHS can utilise existing capacity in the independent sector

- PMLiVE

Kite and Arcellx partner to develop and commercialise multiple myeloma candidate

Arcellx is set to receive an upfront cash payment of $225m and $100m equity investment

- PMLiVE

Implicit bias in treatment impacts clinical trials too

By Ash Rishi

- PMLiVE

WHO report provides data for high levels of antimicrobial resistance in bacteria

GLASS involved 72% of the world’s population, achieving participation from 127 countries

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

Exact Sciences highlights impact of precision oncology portfolio on breast cancer treatment

Data presented at SABCS 2022 supports the company’s cancer diagnostics portfolio

- PMLiVE

FDA approves updated COVID-19 boosters for children aged from six months

The Moderna and Pfizer/BioNTech boosters both target the BA.4/BA.5 omicron subvariants

- PMLiVE

New study links hearing restorative devices to slower rate of memory decline

The use of hearing aids and cochlear implants reduced long-term cognitive decline by 19%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links